Windlas Biotech Ltd

543329

Summary

Fair Value Assessment
Fairly Valued
Fair ValueQ946.64UncertaintyHigh
Close Price990.55Mar 25, 2025
Market Closed
990.55
Price Up by 18.20 | 1.87 %
Previous Close
990.55
Day Range
951.10 – 1,010.00
Year Range
494.70 – 1,197.00
Bid / Ask
Market Cap
20.7 Bil
Volume / Average
9.1 k / 7.0 k
Beta (3-Year)
0.39
Shares Outstanding
20.90 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
Contact
Golf Course Extension Road 705-706, Vatika Professional Point, Gurgaon, HR 122 001
T +91 1242821030
www.windlas.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
1,154

Key Metrics

Income Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
7.26 6.29 5.11 4.63 4.27 3.28
Revenue Growth %
21.49% 23.17% 10.19% 8.59% 29.92% 7.59%
Gross Profit
2.73 2.33 1.85 1.61 1.52 1.17
Gross Profit Margin %
37.52% 37.00% 36.26% 34.65% 35.69% 35.57%
Operating Income
0.67 0.65 0.48 0.41 0.44 0.33
Operating Margin %
9.28% 10.29% 9.39% 8.76% 10.39% 9.90%
EBIT
0.83 0.76 0.54 0.43 0.21 0.26
EBIT Margin %
11.42% 12.12% 10.64% 9.21% 4.95% 7.95%
EBITDA
1.06 0.90 0.67 0.55 0.34 0.35
EBITDA Margin %
14.61% 14.26% 13.06% 11.84% 7.99% 10.78%
Net Income
0.62 0.58 0.43 0.38 0.16 0.16
Net Profit Margin %
8.49% 9.25% 8.35% 8.22% 3.65% 4.94%
Basic EPS
29.59 27.97 19.70 18.58 7.26 7.44
Diluted EPS
29.29 27.88 19.70 18.58 7.26 7.44
Normalized EPS
Total Dividends per Share
5.50 4.00 3.50
Balance Sheet (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
7.47 6.26 5.29 4.91 2.96 3.38
Total Liabilities
2.76 1.76 1.27 0.96 0.97 1.29
Total Debt
0.19 0.04 0.05 0.07 0.32 0.29
Total Equity
4.71 4.50 4.02 3.95 1.99 2.10
Cash And Cash Equivalents
0.05 0.04 0.01 0.16 0.18
Working Capital
2.46 2.60 2.32 2.88 1.01 0.43
Shares Outstanding (Bil)
0.02 0.02
Book Value Per Share
213.98 190.88 180.31
Total Debt To Equity
0.04 0.01 0.01 0.02 0.16 0.14
Cash Flow Statement (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
0.85 1.09 0.61 0.09 0.11 0.25
Cash From Investing Activities
-0.85 -0.92 -0.14 -1.55 -0.20 -0.14
Cash From Financing Activities
-0.01 -0.15 -0.44 1.30 0.01 -0.05
Capital Expenditures
0.38 0.71 0.15 0.06 0.15
Free Cash Flow
0.26 -0.17 0.30 0.44 0.11
Change in Cash
-0.01 0.02 0.03 -0.15 -0.08 0.05

Profile

There is no Key Executive Team data available.
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership

Name
% Total
Shares Held
% Total
Assets
Trend
Prev. 8 Qtrs
Change Amount
Change %
Date
ICICI Pru Pharma Healthcare Diag Gr Not Rated 4.10 1.42 857,651
Feb 28, 2025
ICICI Pru Smallcap Gr 2.02 0.47 422,805
-11,095
2.56%
Feb 28, 2025
UTI Healthcare Reg Gr Not Rated 0.96 1.44 199,738
26,180
15.08%
Feb 28, 2025
Avantis Emerging Markets Equity ETF 0.03 0.00 6,535
Feb 28, 2025
DFA Emerging Mkts ex China Cr Eq Instl 0.02 0.00 4,235
1,301
44.34%
Jan 31, 2025
Total (for Top 5) 7.13 1,490,964
16,386

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top